Introduction
Nucleoside analogues such as AZT(3'-azido-2',3'dideoxythymidine), DDC(2',3'-dideoxycytidine), and DDI(2',3'-dideoxyinosine), which are used for the treatment and prevention of AIDS, show high anti-HIV activity due to their inhibitory effect on the reverse transcription r~------step in the HIV-1 replication cycle De Clercq,1991) . HEPT and TIBO also inhibit reverse transcriptase activity (De Clercq,1991) , but as with nucleoside analogues, emergence of drug-resistant HIV-1 strains has been a problem (Larder et al., 1989; Sarver et al., 1992) . As alternative treatment strategies, anti-HIV-1 drugs with a mode of action other than inhibition of reverse transcriptase activity may be envisaged. Unlike nucleoside analogues, sulphated polysaccharides such as dextran sulphate (OS) (Ito et al., 1987) and curdlan sulphate (Kaneko et al., 1990) and other polyanionic substances such as aurintricarboxylic acid (ATA) (Balzarini et al., 1986) block the binding of the HIV envelope glycoprotein to the cell CD4 receptor (Baba et si., 1988; Mitsuya et aI., 1988) and inhibit giant cell formation between HIV-infected and uninfected cells. If applicable, these polyanionic substances may inhibit the decrease in CD4+ cells in patients with HIV infection and prevent the onset and/or progression of the disease. However, a clinical trial with oral OS administration showed no effect in patients with AIDS or ARC (Abrams et el., 1989) . Other studies showed that following oral administration to humans or rats, OS is not readily absorbed (Lorentsen et al., 1989; Hartman et al., 1990) .
Cyclodextrin (CD) is a circular oligosaccharide with a lower molecular weight and a more rigid structure than dextran. Sulphated CD (CDS) has been reported to have high anti-HIV activity (Anand et al., 1990; Schols et al., 1991; T. Otake et al., personal communication) . Moriya et al. synthesized modified cyclodextrin sulphates(mCDS) and cyclodextrin phosphate(CDP) ( Fig. 1) with high anti-HIV activity, good oral bioavailability and low anti-coagulant activity (Moriya et el., 1991) . In this study, we have evaluated the inhibitory effects of these mCDS and COP on the replication of HIV-1 and HIV-2 as well as the oral bioavailability of mCDS using a bioassay to measure serum drug levels. Table 1 shows the inhibitory effects of CDS, mCDS, and COP on HIV-1-or HIV-2 induced cytopathicity (CPE, cytopathic effect) in MT-4 cells. The anti-HIV activity of mCDS 
Results

Anti-HIVactivffy
Anti-coagulant activity
The anti-coagulant activity of CDS was similar to that of DS. However, the anti-coagulant activity of mCDS11 and mCDS30 was about 1/2, and that of CDP was about 1/14 of the anti-coagulant activity of DS (Table 3) . CDS mCDS11 mCDS30 CDP DS(5000)' Compound a. IC so for giant cell formation between HTLV-lIl e or LAV-2 RoD-infected HUT-78 cells and uninfected MOLT-4 cells corresponds to the 50% inhibitory concentration that reduced the number of giant cells by 50%. Data are mean values for two separate experiments.
Pharmacokinetics in rabbits
After oral administration of mCDS11 at 0.25 g kg-1 to rabbits, serum specimens were collected. The serum mCDS11 concentration was measured using the in vitro anti-HIV-2 activity of these specimens as an index. The serum mCDS11 concentration was 480 fl9 mr' at 1 h after administration, thus indicating high oral bioavailability. Subsequently, the serum drug concentration gradually decreased but it was still 200 fl9 rnl" after 5 h ; after 6 and 8 h it was below the detection limit «200 fl9 ml") . The blood half-life calculated was 4 h (Fig. 2 ).
Inhibition of virus adsorption
Polysulphates such as DS are known to inhibit binding of HIV-1 particles to CD4+ cells. Whether CDS, mCDS and CDP have a similar action was examined by flow cytometry. When MT-4 cells (CD4+ cells) were exposed to HIV-1 particles in the absence of the test compounds, the peak of fluorescence-positive cells was observed on the display. When the MT-4 cells were exposed to HIV-1 in the presence of CDS, mCDS, or CDP at a concentration of 50-300 fl9 mr', the fluorescence was very much weakened, nearly overlapping the fluorescence-negative peak. This suggested that HIV-1 adsorption to the cells was inhibited by the compounds. was higher than that of CDS or CDP; the concentrations of mCDS11 and mCDS30 that inhibited HIV-1 replication (EC so ) were 0.51 and 0.13 fl9 mr", respectively. The activity of mCDS was similar to or higher than that of DS. Each compound inhibited expression of virus antigen in CEM cells at a concentration similar to the concentration that inhibited CPE in MT-4 cells. In addition, each compound inhibited HIV-2 replication at a concentration similar to the concentration that inhibited HIV-1 replication. mCDS30 and CDP were slightly toxic to mock-infected MT-4 cells and CEM cells, but the other compounds were not cytotoxic.
Inhibition of giant cell formation
When HUT-78 cells persistently infected with HIV-1 (HTLV-III B ) or HIV-2 (LAV-2 R o D ) were co-cultured with mock-infected MOLT-4 cells (1 : 1 ratio), giant or multinucleated. syncytial cells were observed after 24 h. DS added at a concentration of 20fl9 rnr" to culture medium inhibited giant cell formation by 50%. The inhibitory effects of mCDS11 and mCDS30 were very marked; their IC so values were 7 and 1 fl9 rnl", respectively ( Table 2) . The inhibitory effect of CDP on giant cell formation was similar to that of DS while the inhibitory effect of CDS was less pronounced. At concentrations similar to those required to inhibit HIY-1-induced giant cell formation, CDS, mCDS, CDP and DS also inhibited giant cell formation in co-cultures of HUT-78/HIV-2 (LAV-2 Ro D ) cells and mock-infected MOLT-4 cells. CDS inhibited giant cell formation induced by HIV-2 at a concentration similar to that of mCDS (Table 2) . MesS02C1
a. Plasma collected from three normal volunteers.
Discussion
.~1 bioavailability in rats than CDS (Moriya et el., 1991) . Further, the present study has shown mCDS to be active against HIV-2 , and to have high oral bioavailability in rabbits.
-.{t
CDS, mCDS, and CDP inhibit HlV-1 binding to the cells, as demonstrated by flow cytometry. These compounds inhibit also giant cell formation. These findings indicate that these compounds akin to other sulphated polysaccharides owe their anti-HIV activity to inhibition of the interaction of the viral envelope glycoprotein with the cell CD4 receptor. To determine whether mCDS acts on the viral envelope glycoprotein or cell CD4 receptors, the Sulphated polysaccharides such as DS have been reported to inhibit selectively HIV-1 and HIV-2 activity in vitro. However, there are no reports showing the in vivo effectiveness of these compounds in humans (Abrams et al., 1989) . DS administered orally to humans is virtually unabsorbed (Lorentsen et al., 1989) . From studies in rats it appears that DS is poorly absorbed from the intestinal tUbe and, moreover, it is degraded to small molecules which are no longer active against HlV (Hartman et al., 1990) . We considered CD optimal as a drug skeleton because it has a smaller molecular weight than the polysaccharides, and contains a rigid cyclic structure that can be retained in the body without being degraded. CDS has been reported to have anti-HlV action in vitro (Anand et al., 1990; Schols et al., 1991; T. Otake et al., personal communication) . In this study mCDS in which lipophilic groups were introduced into CDS was synthesized. A previous study indicated that mCDS has higher anti-HIV-1 activity, lower anti-coagulant activity and higher oral cells or virus was reacted with mCDS11 and washed, and virus infectivity or cell sensitivity to HIV-1 was measured. However, mCDS11 did not act either on the virus or on the cells (data not shown). In addition, mCDS11 did not inhibit the binding of anti-CD4 monoclonal antibody(anti-Leu3a) to MT-4 cells(CD4+ cells) (data not shown). These findings suggest that mCDS11 inhibits the binding of the virus to cells by mechanisms other than irreversible binding to viral envelope glycoprotein or cell CD4 receptors, or masking of the anti-Leu3a antibody binding site in CD4 molecules. mCDS11 and mCDS30 bearing lipophilic groups have higher liposolubility than CDS. The present findings suggest that higher Iiposolubility is associated with higher anti-HIV activity. The lipophilic groups may potentiate the interaction of the compounds with either the envelope glycoprotein (gpI20) of the virus or the cellular CD4 molecules, or both, thus intensifying the inhibition of the virus binding to the cells. Also, introduction of the lipophilic groups led to increased inhibition of giant cell formation between persistently HIV-infected cells and mock-infected CD4+ cells. Further studies are required on the action of the lipophilic groups of mCDS on the cells and virus. CDP showed also that anti-HIV activity results from its inhibitory effect on virus binding to cells. Phosphated inositol, a monosaccharide, has been reported to exhibit anti-HIV-1 activity also. However, this activity is lower than that of sulphated inositol . In this study, CDP showed higher anti-HIV-1 activity than CDS. This may be attributed to the fact that part of the hydroxyl groups of CD in CDP was substituted with chlorine, resulting in higher liposolubility.
Sulphated polysaccharides are notorious for their anticoagulant activity. The anti-coagulant activity of CDS was similar to that of DS, but the anti-coagulant activity of mCDS was 1/2 and that of CDP was 1/14 of that of DS. Thus introduction of lipophilic groups in CDS not only enhanced the anti-HIV activity but also reduced the anticoagulant activity. CDP had lower anti-coagulant activity than mCDS and may be a good anti-HIV drug candidate. However, CDP proved rather cytotoxic in vitro.
Recently, it has been reported that mCDS binds firmly to serum protein and shows anti-HIV activity in the bound form (Moriya et el., 1993) . Therefore, once mCDS has been absorbed and has entered the blood it is difficult to analyse and quantify in an intact form. Thus, pharmacokinetic studies were performed by bioassay. After oral administration of mCDS11 to rabbits, it reached high blood concentration (Fig. 2) . Its half-life was 4 h. After oral administration of DS at a similar dose (0.25 g kg-1 ) , no component showing anti-HIV activity could be detected in the blood by using a similar bioassay. Therefore, mCDS11 may be considered as a sulphated oligosaccha-ride with high oral bioavailability. Similar findings were obtained following oral administration of mCDS11 to rats (Moriya et al., 1991) . However, as the results of a bioassay are relatively crude, studies by chemical analysis are required.
Toxicity was not observed after oral administration of mCDS11 to mice at a dose of 0.5 and 2 g kg-1 d-1 for 5 days (data not shown).
In conclusion, having lipophilic groups in CDS, mCDS showed high anti-HIV activity and selectivity. In addition, the anti-coagulant activity and acute toxicity of mCDS were relatively low, suggesting their high oral bioavailability. This indicates that these compounds should be further pursued for their potential as oral drug candidates in the prophylaxis and/or therapy of HIV infections.
Materials and Experimental procedures: chemistry
General
Melting points were determined in open glass capillaries on a Yamato apparatus (Yamato Kagaku, Tokyo, Japan) and are uncorrected. IR spectrawere recorded on a Perkin-Elmer 1640 instrument (Perkin-Elmer Japan, Yokohama, Japan), NMR spectra on a Bruker AC-200 instrument (Bruker, Tsukuba, Japan) using tetramethylsilane in DMSO-d s and sodium d 4-3trimethylsilylporpionate in D 2 0 as internal standard, and MS spectra on a Hitachi M-2000A instrument (Hitachi, Tokyo, Japan).The elemental analyseswere performed using Perkin-Elmer2400 CHN elemental analyserfor C, H, and N, HitachiZ-8000 atomic absorption spectrophotometer for Na and K, and Yokogawa IC-7000S lon-chromatographic analyser (Yokogawa denki, Musashino, Japan) for Sand CI applyingthe oxygen flask combustion method and also for ionic so,": bcyclodextrin was purchased from NihonSyokuhin Kako Co. Ltd (Tokyo, Japan).
Synthesis of potassium f3-cyclodextrintetradecasulphate (COS)
Sulphur trioxide-pyridine complex (19.90g, 125 mmole) at 60°C was added to a solution of~-cyclodextrin (2.27g, 2 mmole) in pyridine (200 ml) and stirred violently at the same temperature for 6 h. After standing overnight, the supernatant was removed, the residue was dissolved in water (30 ml) and the solution was treated with cation exchange resin Dowex 50W x 8 (W, 200ml) for 30 min. The resin was removed and the mother llquld was adjusted at pH6 with aqueous barium hydroxide and then bariumoxide was added to make the solution at pH7.5. The reaction mixturewas centrifuged to remove the formed precipitates, treated with active charcoal and then stirredwith acidic resinSK-1 B (H'-form. 40 ml) for 20 min. After removal of the resin, the acidic solution was neutralized at pH7.30 with 1% aqueous potassium hydroxide solution, treated with membrane filter of pore size of 4.7Ilm, and then lyophilized to affordcolourless powderof CDS (3.16 g).
IR ( 
Synthesis of potassium e-pentecntoropemeaeoxy-B. cyclodextrin-tetradecaphosphate (COP)
To a solution prepared by a dropwise addition of phosphoryl chloride (9.3 ml, 100 mmole) to pyridine (100 ml) at -10°C was added portionwise~-cyclodextrin (2.27 g, 2 mmole) at -20°C and the mixture was stirred at ambient temperature for 20 h. After removal of the insoluble matter formed, the reaction mixture was poured into ether (300 ml) and resultant precipitates were collected. The precipitates were dissolved in water (100 ml) and the aqueous solution was shaken with ether (150 ml). Precipitates (330 mg, decomposed at 213°C) separated from the aqueous layer were dissolved again in water (30 ml) and treated with an acidic resin SK-1B (H''-forrn, 10ml) for 30min. The aqueous solution was neutralized at pH 7.30 with 0.2 N potassium hydroxide, filtered with Millipore of 4.7 11m pore size, and then lyophilized to afford COP as a colourless powder (320 m~. _ I~(KBr): 3400,1630 3400, , 1520 cm !Ã nal., Calcd. for C42Hs703sCIsx8P03HKx12H20 (2387.96): C, 21.13; H, 3.76; CI, 7.42; P, 10.38; K, 13.10% Found: C, 21.31; H, 3.78; CI, 7.27; P, 10.13; K, 13 .06%.
Synthesis of tris(6-benzylthio-6-deoxY)-f3-cyclodextrin (lIa)
To a suspension of sodium hydride (10.9 g, 63% in paraffin, 257 mmole) in N,N-dimethylformamide (OMF, 500ml) was added benzylmercaptane (33.7 ml, 287 mmole) dropwise at room temperature within 30 min and tris(6-0-mesitylenesulfonyl)-~-cyclodextrin (la, 53.6 g, 32 mmole) was added to the mixture with continuous stirring. After stirring at 50°C for 4 h, the reaction mixture was poured into water (6 I) and the resultant precipitate was collected, washed with acetone (2 I), dissolved in 5% aqueous sodium hydroxide (30 ml) and loaded on a CHP-20 column. Then it was eluted with water (10 I), 65% aqueous methanol (10 I), and 80% aqueous methanol (15 I), successively. The last eluent was concentrated and the residue was washed with acetone and dried to yield colourless powder of tris(6-benzylthio-6-deoxy)-~-cyclodextrin (34.2 g, 74%). mp. 210°C (decomp.). IR (KBr): 3400, 1550, 1498, 1410, 1155, 1030 cm" 1H-NMR (OMSO-d s) 3: 2.5-4.0 (m, 48H), 4.4-4.7 (m, 4H), 4.7-5.0 (m, 7H), 5.6-6.0 (m, 14H), 7.1-7.4 (rn, 15H) p.p.m.
AnaL, Calcd. for CS3Hss032S3X3/2H20 (1430.62): C, 51.11; H, 6.20; S, 6.50%. Found: C, 51.11; H, 6.25; S, 6.68%.
Synthesis of heptakis(6-phenylamino-6-deoxy)-f3cyclodextrin (lib)
A mixture of heptakis (6-0-mesitylenesulfonyl)-~-cyclodextrin (Ib,* 4.0 g, 1.66 mmole) and aniline (20 ml) was refluxed for 2.5 h. The reaction mixture was poured into ether (300 ml) and Synthesis of potassium tris(6-benzylthio-6-deoxY)~f3 cyclodextrin hexadecasulphate (mCOS11) Sulphur trioxide-pyridine complex (6.6 g, 54 mmole) at 100°C was added to a solution of lIa (1.45 g, 1.0 mmole) in pyridine (75 ml) and stirred violently at the same temperature for 8 h.
After cooling to room temperature, the supernatant was decanted off and the residue was triturated with methanol (300 ml) to yield a faintly yellow powder. The powder was washed well with methanol and dissolved in aqueous potassium hydroxide (1.8 g. 32 mmole) solution. The aqueous solution was concentrated to dryness under reduced pressure and the residue was washed again with methanol. The product was purified by Sephadex G-10 column chromatography and then lyophilized to afford colourless powder of potassium mCOS11 (3.11 g, 84.4%). m.p. 217-219°C (decomp. 
Synthesis of potassium heptakis(6-phenylamino-6-deoxY)-f3-cyclodextrin tetradecasulphate (mCOS 30)
Sulphur trioxide-pyridine complex (1.8 g, 11.4 mmole) at 80°C was added to a solution of lib (300 mg, 0.18 mmole) in pyridine (40 ml) and stirred violently at the same temperature for 6 h. After cooling to room temperature, the supernatant was decanted off and the residue was triturated with methanol (300 ml) to yield a faintly brown powder. The powder was washed well with methanol, dissolved in water (5 ml) and neutralized at pH 8 with 10% aqueous sodium hydroxide solution. The aqueous solution was concentrated to dryness under reduced pressure and the residue was washed again with methanol. The product was purified by Sephadex G-10 column chromatography and then lyophilized yield a faintly brown powder of potassium mCOS30 (300 mg). m.p. 215-220°C (decomp.). Anal., Calcd. for CS4H91N702sx14S03NaxO.25Na2S04x21 H 20 (3503.17) C, 28.80; H, 3.83; N, 2.80; S, 13.04; Na, 9.52 ; S (sol-), 0.23%. Found: C, 28.71; H, 3.51; N, 2.71; S, 12.71; Na, 9.44 ; S (S04 2-), 0.23%.
Materials and Experimental procedures: virology
Compounds
Dextran sulphate sodium salt [DS(5000) prepared from dextran with an average molecular weight of 5000] was purchased from Sigma Chemical Co. (S1. Louis, MO).
Viruses
HIV-1(strain HTLV-III B) and HIV-2(strain LAV-2 Ro o ) were obtained from the supernatants of HUT-78/HTLV-IIIB and HUT-78/LAV-2 Ro o cells.
Anti-HIV activity assay
The inhibitory effects of the compounds on HIV-1 and HIV-2 replication were determined by the inhibition of virus-induced cytopathicity in MT-4 cells. Briefly; MT-4 cells were suspended at 3 x 10 s cells mr' and infected with HIV at 100 CCID so.
Immediately after infection, 100 III of the cell suspension was placed into each well of a flat-bottomed 96-well plastic microtitre tray containing various concentrations of the test compounds. After 5 days of incubation at 3rC , the number of viable cells was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MIT) method .
Anti-HIV activity was also determined by monitoring viral antigen expression in CEM cells. CEM cells (10 s cells mr')
were infected with HIV at a MOl of 0.05 and cultured in the presence of various concentrations of the test compounds. On day 4, viral antigen expression was measured by indirect immunofluorescence and laser cytofluorography, using polyclonal antibody as a probe, as described previously .
Cytotoxicities of the compounds were determined by measuring the viabilities of mock-infected CEM and MT-4 cells on days 4 and 5, respectively.
Giant cell formation
MOLT-4 cells ( 5 x 10 s ) were cocultured with an equal number of HUT-78/HTLV-III B or HUT-78/LAV-2 Ro D cells in microtitretray wells containing various concentrations of the test compounds. After 24 h of cocultivation, the number of giant cells was examined microscopically and analysed by laser flow cytofluorography, as described previously (Schols et al., 1989b; .
Virus adsorption assay
The inhibitory effects of the test compounds on virus adsorption were measured by an indirect immunofluorescence-laser flow cytofluorographic method specifically designed for this purpose (Schols et aI., 1989a) . MT-4 cells were exposed to HIV-1 virions in the presence or absence of the test compounds. The cells were incubated for 30 min at 37°C and washed twice in phosphate-buffered saline (PBS) to remove unbound virus. Then a high-titre polyclonal antibody (diluted 1/500 in PBS) was added. After another 30 min of incubation at room temperature, the cells were washed twice with PBS. The cells were then incubated with fluorescein isothiocyanate (FITC)-conjugated F(ab')2 fragments of rabbit anti-human immunoglobulin antibody (diluted 1/30 in PBS) for 30min at room temperature, washed once in PBS, resuspended in 0.5 ml of 0.5% paraformaldehyde in PBS, and analysed by laser flow cytofluorography.
Detection of serum drug levels by bioassay system
Serum drug levels were measured by the bioassay system described previously (Witvrouw et al., 1990) . Female rabbits (Leuven Animal Production Center, Leuven, Belgium) were given mCDS orally via gastric intubation at a dose of 0.25 g kg-1 . At different times after administration of the compound, blood was collected from the rabbit's ear and serum was obtained by centrifugation at low speed. The specimens were stored at -20°C until assayed.
The antiviral assays were based on the inhibitory effect of the serum specimens on HIV-induced cytopathicity in vitro. Briefly, MT-4 cells were suspended in culture medium at 2.5 x lO s cells rnr' and infected with HIV-2 (LAV-2 Ro o ) at 1000 CCID so rnr'. Immediately after infection, the cell suspension was transferred to microtitre tray wells (100 III cell suspension per well) containing various dilutions of the serum specimens. The maximum concentraion of rabbit serum that could be added to the culture medium was 2% because of its toxic action on MT-4 cells. After a 5-day incubation at 37°C, the number of viable cells was assessed by the MIT method as mentioned above. Drug concentrations in the rabbit serum specimens were determined by comparison of their 50% inhibitory concentration (IC so) with the IC so values of the compound tested as such and in the presence of appropriate dilutions of control serum.
Assay of anti-coagulation effect
The anti-coagulation effect of the test compounds was assayed according to Zucker's activated partial thromboplastin time (APIT) method (Zucker et al., 1969) . To 0.1ml of human plasma containing 3.8% citric acid, 0.01ml of the test compound solution (Tris-HCI buffered solution, pH 4.0, 50mM) was added. The mixture was incubated for 2 min at 37°C and 0.1ml of ACTIN (activated cephaloplastin reagent) added. Then, 0.1 ml of a calcium chloride solution (0.02 M) was added, and the time required for coagulation (APTT) was measured.
